Flu season 2026-2027 in Italy: RespiVirNet surveillance restarts, and common-cold viruses lead for now
On 13 November 2026 Italy’s National Institute of Health (Istituto Superiore di Sanità, ISS) released the first seasonal report of RespiVirNet, the national system that tracks acute respiratory infections and the viruses behind them. For the week of 2-8 November an estimated 478,000 cases occurred in Italy, yet the swab results tell a clear story: so far true influenza accounts for only a small share, while rhinoviruses, parainfluenza viruses and adenoviruses predominate.
Background: eight months without data
RespiVirNet combines two streams: epidemiological data reported by “sentinel” general practitioners and paediatricians, and virological data from the national laboratory network that tests respiratory swabs. Reporting had stopped on 6 March 2026, when the Regions suspended data transmission pending rules compliant with personal data protection law.
To restart, the ISS temporarily modified the platform so that it now collects only data without personal identifiers. Talks with the Ministry of Health and the Italian Data Protection Authority on a new regulation are still ongoing.
The figures for 2-8 November
• Estimated acute respiratory infections in the community: 478,371 (442,752 the previous week)
• National incidence: 8.51 cases per 1,000 patients, similar to the same period of the 2025-2026 season
• Trend over the last four weeks: 6.96 → 7.38 → 7.81 → 8.51 cases per 1,000
• Since surveillance began (week of 12 October), about 1.74 million cases have been estimated
• Incidence has just crossed the seasonal baseline threshold (8.01) but remains below the low-intensity threshold (13.77)
• 1,039 sentinel physicians reported data
Who is most affected
• Children aged 0-4: 29.81 cases per 1,000, by far the most affected group
• Ages 5-14: 7.45; 15-24: 8.50; 25-44: 9.45; 45-64: 7.21
• Aged 65 and over: 4.98 cases per 1,000
What the swabs show
For laboratory professionals, the most informative data is the breakdown of identified viruses.
• Sentinel samples: rhinovirus 25.7%, parainfluenza viruses 17.1%, adenovirus 8.6%, influenza viruses only 5.7%
• Hospital samples: rhinovirus again leads (29%), followed by parainfluenza viruses (6.5%) and coronaviruses other than SARS-CoV-2 (6%)
• Of 692 samples tested during the week, 36 were positive for influenza (5.2%): 34 type A, mostly A(H1N1)pdm09, and 2 type B
• In the same set: 125 rhinoviruses, 39 SARS-CoV-2, 31 parainfluenza viruses, 24 other coronaviruses, 15 adenoviruses, a single respiratory syncytial virus and a single metapneumovirus
• From week 42 to week 45, 110 samples tested positive for influenza (102 type A: 62 H1N1pdm09, 10 H3N2, 30 not yet subtyped; 8 type B)
• No influenza A virus unattributable to seasonal strains has been reported
• Influenza and SARS-CoV-2 are more frequent among hospitalised patients aged 65 and over
What it means for testing and patients
At this point in autumn, fever, sore throat and cough are more often caused by “common cold” viruses than by influenza. The clinical pictures overlap, and only laboratory testing can tell them apart.
• Influenza A and B swab tests and SARS-CoV-2 swab tests are most useful when the result changes management: frail or older patients, hospitalised patients, or when antiviral treatment is being considered
• Multiplex molecular panels, which look for several viruses at once, are what allow surveillance to identify rhinoviruses, parainfluenza viruses and adenoviruses
• Tests such as C-reactive protein and a complete blood count with differential do not identify the virus, but help the physician assess inflammation and suspected bacterial superinfection, such as pneumonia
• Antibiotics do not work against viral infections: the decision always rests with the treating physician
Who should take note
• Parents of young children, the age group with the highest incidence
• Older people and patients with chronic conditions, who are at greater risk of complications from influenza and COVID-19: the ISS notes that vaccination campaigns are under way and are recommended, among others, for everyone over 60
• Physicians, paediatricians and laboratories, who once again have a weekly reference for the course of the season
Limitations
• The platform is provisional and collects anonymous data: according to the ISS itself, this partly reduces data quality
• Not all Regions and laboratories have transmitted data yet
• Regional comparisons should be read with caution: Campania, classified as very high incidence, had only 4 active sentinel physicians and Basilicata just one; no participating physicians were reported in Calabria, Aosta Valley and the Province of Bolzano
• Virological data are still being consolidated and may be revised in later reports
• Early-November data cannot predict when the influenza peak will arrive or how intense it will be
In summary
• After an eight-month pause, the ISS has resumed publishing the RespiVirNet report
• An estimated 478,000 acute respiratory infections in the week of 2-8 November, incidence 8.51 per 1,000, in line with last year
• Children under 5 are the most affected
• Rhinoviruses and parainfluenza viruses predominate for now; influenza accounts for about 5-6% of tested samples, mainly A(H1N1)
• The system is not yet fully operational: regional and virological data should be interpreted with caution
Sources:
ISS – EpiCentro, RespiVirNet report; Quotidiano Sanità, 13 November 2026; ANSA, 13 November 2026; Adnkronos, 13 November 2026
Laboratory tests:
Tampone nasale per il virus dell’Influenza A e B, Test per il covid-19: sierologico, tampone molecolare, PCR Proteina C Reattiva, VES, Emocromo
Diseases, symptoms and related pages:
Influenza, H1N1 Virus dell’Influenza A, Febbre, Tosse, Adenovirus, Metapneumovirus, Polmonite bilaterale, Quademic e Norovirus, Long Covid















































Discussion about this post